Chiba University study flags allergy risk in high-binding antibody drugs
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
For the biopharma industry, the study strengthens the case for balancing immune-cell engagement with tolerability in antibody discovery platforms
Subscribe To Our Newsletter & Stay Updated